Stifel Nicolaus Sticks to Its Buy Rating for HEALWELL AI (AIDX)

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on HEALWELL AI on December 11 and set a price target of C$3.80. The company’s shares closed last Friday at C$0.92.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

According to TipRanks, Keywood is an analyst with an average return of -5.9% and a 43.24% success rate. Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, DRI Healthcare, and Vitalhub.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for HEALWELL AI with a C$3.89 average price target.

Based on HEALWELL AI’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of C$40.52 million and a GAAP net loss of C$4.18 million. In comparison, last year the company earned a revenue of C$5.44 million and had a net profit of C$2.58 million

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AIDX in relation to earlier this year.